Skip to content

Gender Related Coping and Survivorship for Genitourinary Cancers

Gender Related Coping and Survivorship for Genitourinary Cancers

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05649306
Enrollment
80
Registered
2022-12-14
Start date
2023-01-20
Completion date
2029-09-30
Last updated
2025-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder Cancer

Keywords

Female, Adult, Genitourinary Cancers

Brief summary

This research is being done to learn more about coping and survivorship of women with bladder cancer, specifically regarding psychosocial distress and sexual dysfunction. This study is a non-therapeutic study and will randomize participants to a standard of care group and education group. Patients in both groups will be asked to complete surveys regarding their mood and sexual function. Patients in the intervention group will be asked to complete attendance diaries regarding educational and support services utilized. Participants' clinical data will also be collected.

Detailed description

The Gender Related Coping and Survivorship Study for Genitourinary Cancers is focused on providing patients with additional education to promote sexual function in female bladder cancer patients with the aim to help decrease demoralization and sexual dysfunction. Patients receiving a cystectomy and patients not receiving a cystectomy will be randomized separately into an additional education or standard of care group. The additional education consists of asking patients to attend the Women and Bladder Cancer Educational Series, Women's Bladder Cancer Support Group meetings, referrals to other support services, receiving supplemental handouts and treating physician led counseling incorporated into standard of care visits. All participants will be asked to complete the Demoralization Scale-II and Female Sexual Function Index at baseline, one-month following treatment, three-months following treatment, six-months following treatment, and one year following treatment. Patients randomized to the additional education group will also be asked to complete an attendance diary one-month following treatment, three-months following treatment, six-months following treatment, and one year following treatment.

Interventions

Study-Specific Patient Handouts, Treating-Provider led counseling, Women's Bladder Cancer Support Group, Women's Bladder Cancer Educational Series, and referrals for additional support services

OTHERQuestionnaires

Female Sexual Function Index, Demoralization Scale-II

OTHERAttendance Diary

Attendance Diaries for the Women's Bladder Cancer Support Group, Women's Bladder Cancer Educational Series, and additional educational and support services utilized

Sponsors

Johns Hopkins University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Females with bladder cancer * Willing to answer surveys regarding their psychosocial health and sexual health

Exclusion criteria

* Not undergoing either active treatment or active surveillance (i.e. patients on hospice care) * Patients with cognitive impairments * Women who are pregnant

Design outcomes

Primary

MeasureTime frameDescription
Use Demoralization Scale-II to assess change in demoralizationBaseline, 1-Month after Treatment, 3-Months after Treatment, 6-Months after Treatment, 1-year after TreatmentEvaluate educational interventions to improve demoralization in females with bladder cancer. The minimum score is 0 and the maximum score 32. Low scores are defined as 0-3, middle scores are defined between 4-10, and high scores are defined as ≥11.

Secondary

MeasureTime frameDescription
Use Female Sexual Function Index (FSFI) to assess change in sexual functionBaseline, 1-Month after Treatment, 3-Months after Treatment, 6-Months after Treatment, 1-year after TreatmentEvaluate if educational interventions improve sexual function in females with bladder cancer. The minimum total score for the FSFI is 2 and the maximum total score is 36. A higher score indicates increased sexual function.
Change in coping as assessed by Demoralization Scale IIBaseline, 1-Month after Treatment, 3-Months after Treatment, 6-Months after Treatment, 1-year after TreatmentAssess how coping in females with bladder cancer differs by stage of bladder cancer. For the Demoralization Scale II, the minimum score is 0 and the maximum score 32. Low scores are defined as 0-3, middle scores are defined between 4-10, and high scores are defined as ≥11.
Change in coping as assessed by the Female Sexual Function Index (FSFI)Baseline, 1-Month after Treatment, 3-Months after Treatment, 6-Months after Treatment, 1-year after TreatmentAssess how coping in females with bladder cancer differs by stage of bladder cancer. The minimum total score for the FSFI is 2 and the maximum total score is 36. A higher score indicates increased sexual function.
SurvivorshipBaseline, 1-Month after treatment, 3-Months after Treatment, 6-Months after Treatment, 1-year after TreatmentAssess survivorship in females with bladder cancer differs by stage of bladder cancer.

Countries

United States

Contacts

Primary ContactMeghan McNamara
mmcnam11@jhmi.edu202-660-6133
Backup ContactArmine Smith
asmith165@jhmi.edu202-660-5561

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026